American firm Thermo Fisher Scientific Inc. has entered into a definitive agreement with Solventum to acquire its Purification & Filtration business for approximately $4.1 billion in cash.
Solventum’s Purification & Filtration business is a leading provider of purification and filtration technologies used in the production of biologics as well as in medical technologies and industrial applications. The Solventum business operates globally with sites across the Americas, Europe, the Middle East, Africa, and the Asia-Pacific region, and has approximately 2,500 colleagues. In 2024, Solventum’s Purification & Filtration business generated approximately $1 billion of revenue.
Solventum’s Purification & Filtration business is highly complementary to Thermo Fisher’s bioproduction business. Thermo Fisher has a leading portfolio of offerings in cell culture media and single-use technologies. Solventum’s innovative filtration portfolio broadens Thermo Fisher’s capabilities in the development and manufacturing of biologics, spanning upstream and downstream workflows.
The transaction is expected to be completed by the end of 2025 and is subject to customary closing conditions and regulatory approvals. Once the transaction closes, Solventum’s Purification & Filtration business will become part of Thermo Fisher's Life Sciences Solutions segment.
Thermo Fisher expects to realise approximately $125 million of adjusted operating income from revenue and cost synergies by year five following the close.
